Silence Therapeutics is a biotechnology company that works on finding novel RNA therapeutics for rare metabolic and cardiovascular diseases. Using its mRNAi GalNAc Oligonucleotide Discovery platform, the company focuses on targeting specific genes in the liver. The company has a range of products in development, including SLN360 and SLN124, which are undergoing Phase I clinical trials for treating various diseases.